Core Insights - The company reported a significant decline in revenue and net profit for Q3 2025, with total revenue at 469 million yuan, down 60.12% year-on-year, and a net loss of 87.25 million yuan, a decrease of 145.31% compared to the same period last year [1][3]. Financial Performance - Total revenue for the company was 469 million yuan, a decrease of 707 million yuan from the same period last year, reflecting a year-on-year decline of 60.12% [1]. - The net profit attributable to shareholders was -87.25 million yuan, down 280 million yuan from the previous year, marking a year-on-year decline of 145.31% [1]. - The net cash inflow from operating activities was -58.21 million yuan, an increase of 241 million yuan compared to the same period last year [1]. Key Financial Ratios - The latest debt-to-asset ratio is 31.92%, a decrease of 2.01 percentage points from the previous quarter, but an increase of 0.19 percentage points compared to the same period last year [3]. - The latest gross profit margin is 33.41%, down 5.45 percentage points from the previous quarter and down 10.00 percentage points year-on-year [3]. - The return on equity (ROE) is -4.60%, a decrease of 13.79 percentage points compared to the same period last year [3]. Earnings Per Share and Turnover Ratios - The diluted earnings per share is -0.32 yuan, a decrease of 1.03 yuan from the same period last year, reflecting a year-on-year decline of 145.31% [3]. - The total asset turnover ratio is 0.16 times, down 0.21 times from the same period last year, representing a year-on-year decline of 56.74% [3]. - The inventory turnover ratio is 0.58 times, down 0.67 times compared to the same period last year, indicating a year-on-year decline of 53.49% [3]. Shareholder Structure - The number of shareholders is 16,800, with the top ten shareholders holding a total of 149 million shares, accounting for 54.81% of the total share capital [3]. - The largest shareholder is Shenzhen Huade Xinrun Equity Investment Enterprise (Limited Partnership) with 28.3 million shares [3].
迪瑞医疗(300396.SZ):2025年三季报净利润为-8725.40万元,同比由盈转亏